UK Supreme Court invalidates Eli Lilly patent relating to Cialis

The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers

28 March 2019 The UK Supreme Court’s decision in Actavis v Eli Lilly confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.

Big Pharma

Eli Lilly enters $35m immunology R&D deal

25 April 2019 Eli Lilly has entered into a $35m global licensing and research agreement with biotech company Avidity Biosciences.

Big Pharma

Eli Lilly avoids sanctions in Teva migraine treatment dispute

13 January 2022 Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.